Back to Newsroom

Innocoll AG Announces First Patient Dosed in the Cogenzia COACT-2 Phase 3 Study for the Treatment of Diabetic Foot Infection

ATHLONE, Ireland, June 15, 2015 (GLOBE NEWSWIRE) — Innocoll AG (Nasdaq:INNL), a global, commercial-stage, specialty pharmaceutical company that develops, manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that the first patient was dosed in the COACT-2 (COgenzia Adjuvant for Complete Therapy) Phase 3 study for the treatment of diabetic foot infections (DFIs) using Cogenzia, Innocoll’s topically applied, bioresorbable collagen sponge. COACT-2 is the second of two pivotal Phase 3 studies for Cogenzia to enroll the first subject. The study is being conducted in both the E.U. and the U.S.

Click here to read more